Activity Overview
This online, on-demand virtual symposium brings together renowned experts in pediatric atopic dermatitis (AD). In this educational program, these experts discuss the latest data regarding topical therapies for the management of mild to moderate AD in pediatric patients, share their perspectives and best practices, and forecast applications of key clinical challenges and questions regarding the utility of topical therapies in this patient population.
This educational activity is an archive of the live virtual symposium held on June 18, 2026.
Target Audience
This educational activity is directed toward health care professionals involved in the management of atopic dermatitis. Specifically, dermatologists, dermatology physician assistants, dermatology nurse practitioners, primary care providers, and nurses.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the real-world negative impact of pediatric AD on the QOL of the child and their family/caregiver
- Evaluate safety and efficacy of FDA-approved novel non-steroidal ATTs for AD in children
- Develop personalized treatment plans incorporating ATTs to manage AD in children based on patient-specific needs and shared goals of therapy
Elaine Siegfried, MD
Professor of Pediatrics and Dermatology
Department of Pediatrics, Division of Pediatric Dermatology
Saint Louis University School of Medicine
Director of Pediatric Dermatology
SSM Health Cardinal Glennon Children’s Hospital
St Louis, MO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient (some relationships have ended): AbbVie, Arcutis, ASLAN Pharmaceuticals, Boehringer Ingelheim, Cara Therapeutics, Dermavant, Incyte Corporation, LEO Pharma, NobelPharma, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi/Genzyme, UCB, Verrica Pharmaceuticals; Other (Contracted Research, institutional compensation): Amgen, Edelife/Pierre Fabre, Incyte Corporation, Janssen, LEO Pharma, NobelPharma, Novan, Pfizer, Sanofi, UCB; Other (Contracted Research, institutional compensation): Amgen, NobelPharma, Pfizer, Regeneron, Sanofi
Lawrence F. Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California San Diego
Rady Children’s Hospital San Diego
San Diego, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient (some relationships have ended): AbbVie, Abeona, Acrotech, Almirall, Amgen, Apogee, Arcutis Biotherapeutics, Aslan, Attovia Therapeutics, Bausch, Bristol Myers Squibb, Castle Biosciences, Chiesi, CorEvitas, Dermata, Dermavant, Formation Bio, Forte, Galderma, ImageneBio, Incyte, Janssen, Kenvue, Kymera, LEO Pharma, Lilly, Novartis, OrthoDerm, Pfizer, Regeneron, Sanofi, Takeda, Teikoku Seiyaku, TrialSpark, TRexBio, UCB, UNION Therapeutics, Verrica; Grant/Research Funding (some relationships have ended): AbbVie, Amgen, Arcutis, Aslan, Bausch, Castle Biosciences, Dermavant, Galderma, Incyte, Pfizer, Target RWE; Ownership interests in publicly traded companies: Dermata; Ownership interests in privately held companies: Dermata, Forte; Executive Role (Officer/Director): Verrica Pharmaceuticals (Board of Directors)
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
